{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:47:39Z","timestamp":1789645659282,"version":"4.0.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T00:00:00Z","timestamp":1354752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s11906-012-0321-4","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T20:12:53Z","timestamp":1354738373000},"page":"25-30","source":"Crossref","is-referenced-by-count":57,"title":["Update on the Angiotensin AT2 Receptor"],"prefix":"10.1007","volume":"15","author":[{"given":"Claudia A.","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Widdop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate M.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,6]]},"reference":[{"key":"321_CR1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/08037050310001057","volume":"12","author":"E Kaschina","year":"2003","unstructured":"Kaschina E, Unger T. Angiotensin AT1\/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12:70\u201388.","journal-title":"Blood Press"},{"key":"321_CR2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/sj.bjp.0705448","volume":"140","author":"RE Widdop","year":"2003","unstructured":"Widdop RE, Jones ES, Hannan RE, et al. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809\u201324.","journal-title":"Br J Pharmacol"},{"key":"321_CR3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1161\/hy1101.096109","volume":"38","author":"D Henrion","year":"2001","unstructured":"Henrion D, Kubis N, Levy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension. 2001;38:1150\u20137.","journal-title":"Hypertension"},{"key":"321_CR4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)37201-5","volume":"284","author":"J Wharton","year":"1998","unstructured":"Wharton J, Morgan K, Rutherford RA, et al. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther. 1998;284:323\u201336.","journal-title":"J Pharmacol Exp Ther"},{"key":"321_CR5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/01.RES.83.12.1182","volume":"83","author":"H Matsubara","year":"1998","unstructured":"Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182\u201391.","journal-title":"Circ Res"},{"key":"321_CR6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pharmthera.2008.08.009","volume":"120","author":"ES Jones","year":"2008","unstructured":"Jones ES, Vinh A, McCarthy CA, et al. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292\u2013316.","journal-title":"Pharmacol Ther"},{"key":"321_CR7","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1210\/me.11.9.1266","volume":"11","author":"L Hein","year":"1997","unstructured":"Hein L, Meinel L, Pratt RE, et al. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol. 1997;11:1266\u201377.","journal-title":"Mol Endocrinol"},{"key":"321_CR8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/01.HYP.0000033224.99806.8A","volume":"40","author":"RE Widdop","year":"2002","unstructured":"Widdop RE, Matrougui K, Levy BI, et al. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension. 2002;40:516\u201320.","journal-title":"Hypertension"},{"key":"321_CR9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI117710","volume":"95","author":"M Stoll","year":"1995","unstructured":"Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651\u20137.","journal-title":"J Clin Invest"},{"key":"321_CR10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.2741\/3289","volume":"14","author":"E Porrello","year":"2009","unstructured":"Porrello E, Delbridge L, Thomas W. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front Biosci. 2009;14:958\u201372.","journal-title":"Front Biosci"},{"key":"321_CR11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/13543784.2012.664131","volume":"21","author":"K Verdonk","year":"2012","unstructured":"Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs. 2012;21:501\u201313.","journal-title":"Expert Opin Investig Drugs"},{"key":"321_CR12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/0006-291X(89)92133-5","volume":"163","author":"S Whitebread","year":"1989","unstructured":"Whitebread S, Mele M, Kamber B, et al. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 1989;163:284\u201391.","journal-title":"Biochem Biophys Res Commun"},{"key":"321_CR13","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1021\/jm049715t","volume":"47","author":"Y Wan","year":"2004","unstructured":"Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995\u20136008.","journal-title":"J Med Chem"},{"key":"321_CR14","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/CIRCULATIONAHA.108.784868","volume":"118","author":"E Kaschina","year":"2008","unstructured":"Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523\u201332.","journal-title":"Circulation"},{"key":"321_CR15","first-page":"147843","volume":"109","author":"F Rompe","year":"2010","unstructured":"\u2022\u2022 Rompe F, Artuc M, Hallberg A, et al. Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor {kappa}B. Hypertension. 2010;109:147843. The first report that identified mechanisms linking AT 2 receptor stimulation with antiinflammatory effects.","journal-title":"Hypertension"},{"key":"321_CR16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.bjp.0705838","volume":"142","author":"XC Li","year":"2004","unstructured":"Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol. 2004;142:821\u201330.","journal-title":"Br J Pharmacol"},{"key":"321_CR17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/01.HYP.34.5.1112","volume":"34","author":"MN Barber","year":"1999","unstructured":"Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999;34:1112\u20136.","journal-title":"Hypertension"},{"key":"321_CR18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1476-5381.2009.00575.x","volume":"159","author":"S Bosnyak","year":"2010","unstructured":"\u2022\u2022 Bosnyak S, Welungoda IK, Hallberg A, et al. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709\u201316. Comprehensive dose-ranging study of the in vitro and in vivo vascular effects of Compound 21.","journal-title":"Br J Pharmacol"},{"key":"321_CR19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/HYPERTENSIONAHA.112.196022","volume":"60","author":"K Verdonk","year":"2012","unstructured":"\u2022 Verdonk K, Durik M, Abd-Alla N, et al. Compound 21 Induces Vasorelaxation via an Endothelium- and Angiotensin II Type 2 Receptor-Independent Mechanism \/ Novelty and Significance. Hypertension. 2012;60:722\u20139. A controversial study that reported off-target effects of the AT 2 receptor agonist Compound 21, albeit at concentrations up to 10,000-fold higher than its affinity at AT 2 receptors.","journal-title":"Hypertension"},{"key":"321_CR20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.145037","volume":"55","author":"E Moltzer","year":"2010","unstructured":"Moltzer E, Verkuil AV, van Veghel R, et al. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation. Hypertension. 2010;55:516\u201322.","journal-title":"Hypertension"},{"key":"321_CR21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/HYPERTENSIONAHA.112.197046","volume":"60","author":"D Henrion","year":"2012","unstructured":"Henrion D. Why do we need a selective angiotensin II type 2 receptor agonist? Hypertension. 2012;60:616\u20137.","journal-title":"Hypertension"},{"key":"321_CR22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0031-6997(25)06641-4","volume":"26","author":"D Regoli","year":"1974","unstructured":"Regoli D, Park WK, Rioux F. Pharmacology of angiotensin. Pharmacol Rev. 1974;26:69\u2013123.","journal-title":"Pharmacol Rev"},{"key":"321_CR23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","volume":"52","author":"M Gasparo de","year":"2000","unstructured":"de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415\u201372.","journal-title":"Pharmacol Rev"},{"key":"321_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/CS20110036","volume":"121","author":"S Bosnyak","year":"2011","unstructured":"\u2022\u2022 Bosnyak S, Jones ES, Christopoulos A, et al. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci. 2011;121:297\u2013303. First study to directly compare a range of Ang peptides in the same study to determine AT 2 :AT 1 receptor selectivity.","journal-title":"Clin Sci"},{"key":"321_CR25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/HYPERTENSIONAHA.107.103242","volume":"51","author":"SH Padia","year":"2008","unstructured":"Padia SH, Kemp BA, Howell NL, et al. Conversion of Renal Angiotensin II to Angiotensin III Is Critical for AT2 Receptor Mediated Natriuresis In Rats. Hypertension. 2008;51:460\u20135.","journal-title":"Hypertension"},{"key":"321_CR26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1161\/01.HYP.0000254833.85106.4d","volume":"49","author":"SH Padia","year":"2007","unstructured":"Padia SH, Kemp BA, Howell NL, et al. Intrarenal Aminopeptidase N Inhibition Augments Natriuretic Responses to Angiotensin III in Angiotensin Type 1 Receptor-Blocked Rats. Hypertension. 2007;49:625\u201330.","journal-title":"Hypertension"},{"key":"321_CR27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/01.HYP.0000196950.48596.21","volume":"47","author":"SH Padia","year":"2006","unstructured":"Padia SH, Howell NL, Siragy HM, et al. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537\u201344.","journal-title":"Hypertension"},{"key":"321_CR28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/01.HYP.0000160325.59323.b8","volume":"45","author":"PE Walters","year":"2005","unstructured":"Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1\u20137) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension. 2005;45:960\u20136.","journal-title":"Hypertension"},{"key":"321_CR29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/cvr\/cvm021","volume":"77","author":"A Vinh","year":"2008","unstructured":"Vinh A, Widdop RE, Drummond GR, et al. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008;77:178\u201387.","journal-title":"Cardiovasc Res"},{"key":"321_CR30","doi-asserted-by":"crossref","first-page":"192567","DOI":"10.1155\/2012\/192567","volume":"2012","author":"S Bosnyak","year":"2012","unstructured":"\u2022 Bosnyak S, Widdop RE, Denton KM, et al. Differential mechanisms of Ang (1\u20137)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int J Hypertens. 2012;2012:192567. Striking difference in the vascular phenotype of Ang (1\u20137) given acutely to either young-adult or aged conscious rats.","journal-title":"Int J Hypertens"},{"key":"321_CR31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1021\/jm030921v","volume":"47","author":"U Rosenstrom","year":"2004","unstructured":"Rosenstrom U, Skold C, Lindeberg G, et al. A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4\u20135 of angiotensin II. J Med Chem. 2004;47:859\u201370.","journal-title":"J Med Chem"},{"key":"321_CR32","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1021\/jm049651m","volume":"47","author":"P Johannesson","year":"2004","unstructured":"Johannesson P, Erdelyi M, Lindeberg G, et al. AT2-selective angiotensin II analogues containing tyrosine-functionalized 5,5-bicyclic thiazabicycloalkane dipeptide mimetics. J Med Chem. 2004;47:6009\u201319.","journal-title":"J Med Chem"},{"key":"321_CR33","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/jm2015099","volume":"55","author":"AM Murugaiah","year":"2012","unstructured":"\u2022\u2022 Murugaiah AM, Wu X, Wallinder C, et al. From the first selective non-peptide AT(2) receptor agonist to structurally related antagonists. J Med Chem. 2012;55:2265\u201378. A recent report of the development of a nonpeptide AT 2 receptor antagonist by minor substitutions to the structure of Compound 21.","journal-title":"J Med Chem"},{"key":"321_CR34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/HYPERTENSIONAHA.110.164301","volume":"57","author":"ES Jones","year":"2011","unstructured":"\u2022\u2022 Jones ES, Del Borgo MP, Kirsch JF, et al. A Single beta-Amino Acid Substitution to Angiotensin II Confers AT(2) Receptor Selectivity and Vascular Function. Hypertension. 2011;57:570\u20136. Describes how a simple beta-amino acid substitution into the Ang II molecule dramatically alters AT 2 :AT 1 receptor selectivity and function.","journal-title":"Hypertension"},{"key":"321_CR35","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/HJH.0b013e328335d291","volume":"28","author":"MP Ocaranza","year":"2010","unstructured":"Ocaranza MP, Lavandero S, Jalil JE, et al. Angiotensin-(1\u20139) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens. 2010;28:1054\u201364.","journal-title":"J Hypertens"},{"key":"321_CR36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1113\/jphysiol.2010.203075","volume":"589","author":"M Flores-Munoz","year":"2011","unstructured":"Flores-Munoz M, Smith NJ, Haggerty C, et al. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol. 2011;589:939\u201351.","journal-title":"J Physiol"},{"key":"321_CR37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/HYPERTENSIONAHA.111.177485","volume":"59","author":"M Flores-Munoz","year":"2012","unstructured":"\u2022 Flores-Munoz M, Work LM, Douglas K, et al. Angiotensin-(1\u20139) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension. 2012;59:300\u20137. Antifibrotic effect ascribed to chronic infusion of Ang (1\u20139) acting at AT 2 receptors, although a contribution by other metabolized Ang peptides and mechanisms needs to be fully ruled out.","journal-title":"Hypertension"},{"key":"321_CR38","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139. Circ Res. 2000;87:E1\u20139.","journal-title":"Circ Res"},{"key":"321_CR39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/HYPERTENSIONAHA.111.184788","volume":"59","author":"SH Padia","year":"2012","unstructured":"Padia SH, Kemp BA, Howell NL, et al. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension. 2012;59:437\u201345.","journal-title":"Hypertension"},{"key":"321_CR40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.HYP.0000251881.89610.ee","volume":"49","author":"LJ Salomone","year":"2007","unstructured":"Salomone LJ, Howell NL, McGrath HE, et al. Intrarenal dopamine D1-like receptor stimulation induces natriuresis via an angiotensin type-2 receptor mechanism. Hypertension. 2007;49:155\u201361.","journal-title":"Hypertension"},{"key":"321_CR41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.112.191403","volume":"60","author":"BA Kemp","year":"2012","unstructured":"\u2022\u2022 Kemp BA, Bell JF, Rottkamp DM, et al. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension. 2012;60:387\u201395. Current paper from a series of publications that shows Ang III, but not Ang II or Ang (1\u20137), causes AT2 receptor mediated natriuresis.","journal-title":"Hypertension"},{"key":"321_CR42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1161\/HYPERTENSIONAHA.111.178715","volume":"59","author":"RD Brown","year":"2012","unstructured":"Brown RD, Hilliard LM, Head GA, et al. Sex Differences in the Pressor and Tubuloglomerular Feedback Response to Angiotensin II. Hypertension. 2012;59:129\u201335.","journal-title":"Hypertension"},{"key":"321_CR43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/HYPERTENSIONAHA.108.114058","volume":"52","author":"AK Sampson","year":"2008","unstructured":"Sampson AK, Moritz KM, Jones ES, et al. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 2008;52:666\u201371.","journal-title":"Hypertension"},{"key":"321_CR44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/HYPERTENSIONAHA.110.166827","volume":"57","author":"LM Hilliard","year":"2011","unstructured":"\u2022\u2022 Hilliard LM, Nematbakhsh M, Kett MM, et al. Gender Differences in Pressure-Natriuresis and Renal Autoregulation Role of the Angiotensin Type 2 Receptor. Hypertension. 2011;57:275\u201382. A study demonstrating the greater functional role of AT 2 receptors in renal vasculature in female, as compared to male, rats.","journal-title":"Hypertension"},{"key":"321_CR45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/HYPERTENSIONAHA.111.184986","volume":"59","author":"LM Hilliard","year":"2012","unstructured":"\u2022\u2022 Hilliard LM, Jones ES, Steckelings UM, et al. Sex-Specific Influence of Angiotensin Type 2 Receptor Stimulation on Renal Function. Hypertension. 2012;59:409\u201314. First report showing enhanced AT 2 receptor-mediated renal vasodilator response to Compound 21 in female, as compared to male, rats.","journal-title":"Hypertension"},{"key":"321_CR46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1161\/HYPERTENSIONAHA.111.180158","volume":"59","author":"A Rehman","year":"2012","unstructured":"\u2022\u2022 Rehman A, Leibowitz A, Yamamoto N, et al. Angiotensin Type 2 Receptor Agonist Compound 21 Reduces Vascular Injury and Myocardial Fibrosis in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension. 2012;59:291\u20139. One of the first studies to show cardiac antifibrotic effects following chronic treatment with Compound 21, although its potential inhibition by the AT 2 receptor antagonist PD123319 was not examined.","journal-title":"Hypertension"},{"key":"321_CR47","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1161\/HYPERTENSIONAHA.111.185496","volume":"59","author":"L Paulis","year":"2012","unstructured":"\u2022\u2022 Paulis L, Becker STR, Lucht K, et al. Direct Angiotensin II Type 2 Receptor Stimulation in N-Nitro-l-Arginine-Methyl Ester- Induced Hypertension. Hypertension. 2012;59:485\u201392. One of the first studies to show vessel remodeling following chronic treatment with Compound 21, although its potential inhibition by the AT 2 receptor antagonist PD123319 was not examined.","journal-title":"Hypertension"},{"key":"321_CR48","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/HYPERTENSIONAHA.110.164202","volume":"57","author":"LC Matavelli","year":"2011","unstructured":"\u2022 Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular Hypertension. Hypertension. 2011;57:308\u201313. One of the first studies to show anti-inflammatory effects of Compound 21 in the kidney after short-term treatment with Compound 21.","journal-title":"Hypertension"},{"key":"321_CR49","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1097\/HJH.0b013e3283311ba1","volume":"27","author":"P Gelosa","year":"2009","unstructured":"Gelosa P, Pignieri A, F\u00e4ndriks L, et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444\u201351.","journal-title":"J Hypertens"},{"key":"321_CR50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11906-012-0291-6","volume":"14","author":"S Foulquier","year":"2012","unstructured":"Foulquier S, Steckelings UM, Unger T. Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep. 2012;14:403\u20139.","journal-title":"Curr Hypertens Rep"},{"key":"321_CR51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/FJC.0b013e3182444110","volume":"59","author":"AB Jehle","year":"2012","unstructured":"Jehle AB, Xu Y, Dimaria JM, et al. A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice. J Cardiovasc Pharmacol. 2012;59:363\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"key":"321_CR52","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/STROKEAHA.108.531509","volume":"40","author":"CA McCarthy","year":"2009","unstructured":"McCarthy CA, Vinh A, Callaway JK, et al. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke. 2009;40:1482\u20139.","journal-title":"Stroke"},{"key":"321_CR53","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 McCarthy CA, Vinh A, Broughton BR, et al. Angiotensin II Type 2 Receptor Stimulation Initiated After Stroke Causes Neuroprotection in Conscious Rats. Hypertension. 2012, Oct 22 [Epub ahead of print]. Proof-of-principle report showing that CGP42112, given centrally 6\u00a0hours after stroke in conscious spontaneously hypertensive rats, still evoked neuroprotection.","DOI":"10.1097\/01.hjh.0000420832.63719.cb"},{"key":"321_CR54","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lee S, Brait V, Arumugam T, et al. Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med. 2012, 4: Aug 24 [Epub ahead of print]. Proof-of-principle report showing that CGP42112, given peripherally at the time of ischaemia\/reperfusion in anaesthetised mice, evoked neuroprotection.","DOI":"10.1186\/2040-7378-4-16"},{"key":"321_CR55","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jneumeth.2011.06.009","volume":"202","author":"N Shraim","year":"2011","unstructured":"Shraim N, Mertens B, Clinckers R, et al. Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT2 receptor agonist, to the striatum in rats. J Neurosci Methods. 2011;202:137\u201342.","journal-title":"J Neurosci Methods"},{"key":"321_CR56","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1113\/expphysiol.2011.058578","volume":"96","author":"AP Mecca","year":"2011","unstructured":"\u2022 Mecca AP, Regenhardt RW, O'Connor TE, et al. Cerebroprotection by angiotensin-(1\u20137) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084\u201396. First report showing that Ang (1\u20137) can also evoke neuroprotective effects.","journal-title":"Exp Physiol"},{"key":"321_CR57","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00213-012-2639-7","volume":"222","author":"S Tota","year":"2012","unstructured":"Tota S, Hanif K, Kamat PK, et al. Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology (Berl). 2012;222:185\u2013202.","journal-title":"Psychopharmacology (Berl)"},{"key":"321_CR58","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/jcbfm.2011.133","volume":"32","author":"F Jing","year":"2012","unstructured":"\u2022\u2022 Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012;32:248\u201355. First report on the improved cognitive effects of Compound 21.","journal-title":"J Cereb Blood Flow Metab"},{"key":"321_CR59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20110677","volume":"123","author":"M Horiuchi","year":"2012","unstructured":"\u2022 Horiuchi M, Iwanami J, Mogi M. Regulation of angiotensin II receptors beyond the classical pathway. Clin Sci. 2012;123:193\u2013203. An excellent recent review summarising a number of aspects of nonclassical Ang signaling that are not covered in the current update.","journal-title":"Clin Sci"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-012-0321-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-012-0321-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-012-0321-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T08:34:29Z","timestamp":1745397269000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-012-0321-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,6]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1007\/s11906-012-0321-4","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,6]]}}}